Gelesis, Inc.

A mere four days after announcing a potential link-up, troubled US group Nektar Therapeutics and UK healthcare holding company PureTech have called off merger talks which had taken seasoned observers

Data from the Gelesis -sponsored LIGHT UP study demonstrated the safety and effectiveness of the company’s GS200’s weight-loss device when used to aid weight loss in overweight or obese patients wh

PureTech Health plc is turning to its wholly owned pipeline as a potential future value driver following a disappointing loss last year as it increased its R&D spend. While revenues were up by 47.8%

Merging with a special purpose acquisition corporation (SPAC) can be an attractive alternative to an initial public offering for biopharmaceutical companies looking to go public, but SPACs have begun